Cytostatic and cytotoxic activity of lymphokine-activated killer cell supernatants

Evan M. Hersh, Philip Scuderi, William J. Grimes, Anita Chong, Jacqueline L. Brailey, Charles R. Gschwind, Sydney E. Salmon

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Incubation of peripheral blood mononuclear cells with interleukin-2 (IL-2) results in the release of a factor which is cytostatic and cytotoxic both to tumor cell lines (A375M, A375P, C480, MCF-7, Hey) and fresh tumor cells (in the human tumor cloning assay), including breast cancer, colon cancer, melanoma, myeloma and ovarian cancer. The factor cannot be detected in a 4-h chromium-release assay, but is best demonstrated after tumor cells have been to it for exposed 3 days. The factor is not cytotoxic to normal peripheral blood leukocytes or normal fibroblasts, and is not toxic to certain targets sensitive to lymphokine-activated killer (LAK) cells, such as K562 and Daudi cells. The factor is diffusible, non-dialyzable, relatively stable to heat and acid and does not contain appreciable amounts of targets resistant to interferon-α and β, tumor necrosis factor β and interleukin-1. The data suggest that there are several mechanisms of LAK cell activity against tumor cells including one which requires direct interaction of LAK and tumor cells and one which is mediated by LAK cell supernatant. The former is detected by 4-h chromium release while the latter is not.

Original languageEnglish (US)
Pages (from-to)65-70
Number of pages6
JournalCancer Immunology Immunotherapy
Issue number1
StatePublished - Jan 1989

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Cytostatic and cytotoxic activity of lymphokine-activated killer cell supernatants'. Together they form a unique fingerprint.

Cite this